International: +1-347-960-6455
US/Canada Toll Free:+1-888-778-7886
| Report Code: PP10156 | Published: August 2019 | Pages: 95 | Available format: |
| Therapeutic Area(s): | Others | Report Type: Indication Pipeline Reports |
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Drugs by Phase
1.3.2 Pipeline Drugs by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By geography
2.2.1.3 By designation
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Disease Overview
4.2 Causes and Risk Factors
4.3 Prognosis
4.4 Signs and Symptoms
4.5 Pathophysiology
4.6 Diagnosis
4.7 Treatment
4.8 Key Drivers
4.8.1 Technological Advancements for Drug Manufacturing
4.8.2 Positive Clinical Results of the Pipeline Drugs
4.8.3 Growing Development of Small Molecule Therapeutics
4.9 Key Barriers
4.9.1 Multiple Phenotype and Challenges in Diagnosis
4.9.2 Expensive Therapy
4.10 Technology Overview
4.10.1 Hydroxyl Dendrimer Technology
4.11 Drug Designations
Chapter 5. Pipeline Drugs Outlook
5.1 ALD Pipeline Drugs Snapshot
5.1.1 Pipeline Drugs Snapshot by Phase
5.1.2 Pipeline Drugs Snapshot by Route of Administration
5.1.3 Pipeline Drugs Snapshot by Company
Chapter 6. Pipeline Products
6.1 Phase III
6.1.1 Lenti-D
6.1.1.1 Clinical trials
6.1.1.2 Clinical trial results
6.1.1.3 Strategic development
6.1.1.4 Designations
6.1.1.5 Technology
6.1.1.6 Financing
6.1.1.7 Name Change
6.1.2 Xxxx
6.1.2.1 Clinical trials
6.1.2.2 Clinical trial results
6.1.2.3 Strategic development
6.1.2.4 Designations
6.1.2.5 Financing
6.2 Phase I
6.2.1 SOM1201
6.2.1.1 Other development
6.2.1.2 Financing
6.2.2 Xxxx
6.2.2.1 Pre-clinical studies
6.2.2.2 Clinical trials
6.2.2.3 Clinical trial results
6.2.2.4 Designation
6.2.2.5 Technology
6.2.3 Xxxx
6.2.3.1 Clinical trials
6.2.3.2 Financing
6.3 Pre-clinical
6.3.1 VK0214
6.3.1.1 Pre-clinical studies
6.3.1.2 Strategic developments
6.3.1.3 Designation
6.3.2 Xxxx
6.4 Inactive
6.4.1 PXL065
6.4.1.1 Pre-clinical studies
6.4.1.2 Strategic development
6.4.1.3 Financing
6.4.2 Xxxx
6.4.2.1 Pre-clinical studies
6.5 Unknown Phase
6.5.1 Xxxx
6.5.1.1 Strategic development
Chapter 7. Clinical Trials Review
7.1 Clinical Trials by Geography
7.2 Clinical Trials by Trial Status
Chapter 8. Regulatory Framework for Drug Approval
8.1 U.S.
8.2 Europe
8.2.1 Centralized Procedure
8.2.2 Mutual Recognition Procedure
8.2.3 Decentralized Procedure
8.2.4 Nationalized Procedure
8.3 Japan
Chapter 9. Competitive Landscape
9.1 Summary of Strategic Development Activities
9.2 Attribute Analysis
9.3 Expected Launch Time of Phase III Clinical Stage Products
9.4 Key Winning Strategies
9.4.1 Technological Advancements
9.4.2 Collaborations and Partnerships
9.4.3 Acquisitions
9.4.4 Designations
Chapter 10. Company Profiles
10.1 Poxel SA
10.1.1 Business Overview
10.1.2 Product and Service Offerings
10.2 Xxxx
10.2.1 Business Overview
10.2.2 Product and Service Offerings
10.3 Xxxx
10.3.1 Business Overview
10.3.2 Product and Service Offerings
10.4 Xxxx
10.4.1 Business Overview
10.4.2 Product and Service Offerings
10.5 Xxxx
10.5.1 Business Overview
10.5.2 Product and Service Offerings
10.6 Xxxx
10.6.1 Business Overview
10.6.2 Product and Service Offerings
10.7 Xxxx
10.7.1 Business Overview
10.7.2 Product and Service Offerings
10.8 Xxxx
10.8.1 Business Overview
10.8.2 Product and Service Offerings
10.9 Xxxx
10.9.1 Business Overview
10.9.2 Product and Service Offerings
10.10 Xxxx
10.10.1 Business Overview
10.10.2 Product and Service Offerings
Chapter 11. Appendix
11.1 Recently Organized/Held Seminars and Conferences
11.2 Upcoming Conferences
11.3 Sources and References
11.4 Abbreviations
11.5 Related Reports
LIST OF TABLES
TABLE 1 COMPANY BENCHMARKING BASED ON DRUG CANDIDATES
TABLE 2 DESCRIPTION OF LENTI-D
TABLE 3 CLINICAL TRIALS OF LENTI-D
TABLE 4 DESCRIPTION OF XXXX
TABLE 5 CLINICAL TRIALS OF XXXX
TABLE 6 DESCRIPTION OF SOM1201
TABLE 7 DESCRIPTION OF XXXX
TABLE 8 CLINICAL TRIALS OF XXXX
TABLE 9 DESCRIPTION OF XXXX
TABLE 10 CLINICAL TRIALS OF XXXX
TABLE 11 DESCRIPTION OF VK0214
TABLE 12 DESCRIPTION OF PXL065
TABLE 13 DESCRIPTION OF XXXX
TABLE 14 COLLABORATIONS AND LICENSING AGREEMENTS
TABLE 15 ACQUISITIONS
TABLE 16 EXPECTED LAUNCH TIME OF PHASE III CLINICAL STAGE PRODUCTS
TABLE 17 POXEL SA – AT A GLANCE
TABLE 18 PIPELINE PRODUCTS
TABLE 19 BLUEBIRD BIO INC. – AT A GLANCE
TABLE 20 PIPELINE PRODUCTS
TABLE 21 XXXX – AT A GLANCE
TABLE 22 PIPELINE PRODUCTS
TABLE 23 XXXX– AT A GLANCE
TABLE 24 XXXX – AT A GLANCE
TABLE 25 PIPELINE PRODUCTS
TABLE 26 VIKING THERAPEUTICS INC. – AT A GLANCE
TABLE 27 PIPELINE PRODUCTS
TABLE 28 XXXX – AT A GLANCE
TABLE 29 PIPELINE PRODUCTS
TABLE 30 XXXX – AT A GLANCE
TABLE 31 PIPELINE PRODUCTS
TABLE 32 XXXX – AT A GLANCE
TABLE 33 PIPELINE PRODUCTS
TABLE 34 XXXX – AT A GLANCE
TABLE 35 RECENTLY ORGANIZED SEMINARS AND CONFERENCES
TABLE 36 UPCOMING SEMINARS AND CONFERENCES
TABLE 37 SOURCES & REFERENCESS
TABLE 38 ABBREVIATION
LIST OF FIGURES
FIG 1 RESEARCH METHODOLOGY
FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY GEOGRAPHY
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 5 CORE SIGNALING PATHWAYS IN ALD
FIG 6 ALD PIPELINE DRUGS SNAPSHOT, BY PHASE (2019)
FIG 7 ALD PIPELINE DRUGS SNAPSHOT, BY ROUTE OF ADMINISTRATION (2019)
FIG 8 BREAKDOWN OF CLINICAL TRIALS, BY GEOGRAPHY
FIG 9 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 10 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)
FIG 11 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)
FIG 12 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU
FIG 13 MARKETING AUTHORIZATION PROCEDURES IN EU
FIG 14 CENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 15 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL
FIG 16 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 17 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN
FIG 18 EXPECTED LAUNCH TIME